Innate Pharma Company Profile (NASDAQ:IPHYF)

About Innate Pharma (NASDAQ:IPHYF)

Innate Pharma logo

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: NASDAQ:IPHYF
  • CUSIP: N/A
  • Web: N/A
Average Prices:
  • 50 Day Moving Avg: $12.57
  • 200 Day Moving Avg: $12.61
  • 52 Week Range: $10.72 - $16.55
P/E:
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $79.68 million
  • Price / Sales: N/A
  • Book Value: $1.53 per share
  • Price / Book: 7.82
Profitability:
  • EBITDA: ($4,690,000.00)
Misc:
  • Average Volume: 1,355 shs.
 

Frequently Asked Questions for Innate Pharma (NASDAQ:IPHYF)

What is Innate Pharma's stock symbol?

Innate Pharma trades on the NASDAQ under the ticker symbol "IPHYF."

Who are some of Innate Pharma's key competitors?

How do I buy Innate Pharma stock?

Shares of Innate Pharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Innate Pharma's stock price today?

One share of Innate Pharma stock can currently be purchased for approximately $11.96.


MarketBeat Community Rating for Innate Pharma (NASDAQ IPHYF)
Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  39 (Vote Outperform)
Underperform Votes:  47 (Vote Underperform)
Total Votes:  86
MarketBeat's community ratings are surveys of what our community members think about Innate Pharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Innate Pharma (NASDAQ:IPHYF) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: N/A
Consensus Price Target History for Innate Pharma (NASDAQ:IPHYF)
Price Target History for Innate Pharma (NASDAQ:IPHYF)
Analysts' Ratings History for Innate Pharma (NASDAQ:IPHYF)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/30/2017HC WainwrightInitiated CoverageBuy -> BuyLowView Rating Details
12/5/2016Leerink SwannReiterated RatingBuyN/AView Rating Details
(Data available from 10/23/2015 forward)

Earnings

Earnings History for Innate Pharma (NASDAQ:IPHYF)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Innate Pharma (NASDAQ:IPHYF)

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Innate Pharma (NASDAQ:IPHYF)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Innate Pharma (NASDAQ:IPHYF)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Innate Pharma (NASDAQ:IPHYF)
Latest Headlines for Innate Pharma (NASDAQ:IPHYF)
Source:
Loading headlines, please wait.

Social

Chart

Innate Pharma (IPHYF) Chart for Monday, October, 23, 2017

This page was last updated on 10/23/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.